10-Q: FibroGen Narrows Losses, Advances Cancer & Anemia Programs

FibroGen reported significantly reduced net losses and advanced its key clinical programs for prostate cancer and anemia, following the divestiture of its China operations.

Summary

• FibroGen reported a net income of $200.6 million for the three months ended September 30, 2025, a substantial improvement from a net loss of $17.1 million in the same period of 2024.
• For the nine months ended September 30, 2025, net income was $197.7 million, compared to a net loss of $65.6 million for the nine months ended September 30, 2024.
• Loss from continuing operations for Q3 2025 was $13.1 million, down from $48.3 million in Q3 2024.
• The company completed the sale of its China operations to AstraZeneca Treasury Limited on August 29, 2025, for a total consideration of $220.4 million, which included $85.0 million in enterprise value and $135.4 million in net cash held in China.
• Proceeds from the China divestiture enabled the repayment of $80.9 million in senior secured term loan facilities with Morgan Stanley Tactical Value (MSTV), including $75.0 million principal, $0.4 million outstanding interest, and $5.5 million in related premium and fees.
• Cash and cash equivalents increased to $117.975 million as of September 30, 2025, from $50.482 million at December 31, 2024.
• FibroGen initiated a Phase 2 monotherapy dose optimization study of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for metastatic castration-resistant prostate cancer (mCRPC) in the third quarter of 2025.
• A positive Type-C meeting with the U.S. Food and Drug Administration (FDA) in July 2025 resulted in alignment on several elements of the proposed Phase 3 study design for roxadustat in anemia associated with lower-risk myelodysplastic syndromes (MDS).
• Total operating costs and expenses from continuing operations decreased significantly to $6.5 million for Q3 2025 from $47.8 million for Q3 2024, primarily due to a restructuring charge in 2024 not recurring, lower facilities-related expenses, reduced stock-based compensation, and termination of pamrevlumab programs.
• The accumulated deficit was reduced to $1.7 billion as of September 30, 2025, from $1.89 billion at December 31, 2024.

Sentiment

Score: 7

Explanation: The company achieved a significant net income driven by the divestiture of its China operations, substantially improving its liquidity and balance sheet. Key pipeline assets, FG-3246 and roxadustat in MDS, are progressing with positive regulatory alignment and trial initiations. While continuing operations still incur losses, the strategic refocus and strengthened financial position are positive indicators for future stability and development.

Positives

• Achieved a net income of $200.6 million for Q3 2025, a significant turnaround from a net loss of $17.1 million in Q3 2024.
• Successfully divested China operations for $220.4 million, substantially improving liquidity and financial position.
• Repaid $80.9 million in senior secured term loan facilities, eliminating a significant debt burden and associated financial covenants.
• Cash and cash equivalents increased to $117.975 million as of September 30, 2025, from $50.482 million at December 31, 2024, strengthening the balance sheet.
• Initiated a Phase 2 monotherapy dose optimization study for FG-3246 in mCRPC, advancing a key oncology pipeline asset.
• Received positive Type-C meeting feedback from the FDA for roxadustat in lower-risk MDS, establishing alignment on Phase 3 study design elements and a clear regulatory path forward.
• Realized significant reductions in operating costs and expenses, driven by strategic restructuring and the termination of the pamrevlumab programs.
• Believes existing cash and cash equivalents are sufficient to fund planned operating requirements for at least 12 months following the issuance of the financial statements.

Negatives

• Continuing operations still reported a loss of $13.1 million for Q3 2025 and $32.4 million for the nine months ended September 30, 2025, indicating ongoing operational burn.
• Incurred a $6.6 million loss on debt extinguishments due to the early repayment of the MSTV loan.
• Total revenue from continuing operations remains low at $1.1 million for Q3 2025 and $5.2 million for the nine months ended September 30, 2025.
• Drug product revenue from the Astellas Japan Agreement saw a reduction of $0.4 million for Q3 2025 and $3.9 million for 9M 2024 due to variable consideration adjustments.
• The accumulated deficit remains substantial at $1.7 billion as of September 30, 2025.
• Does not expect to receive most or all additional potential milestones under the Astellas Japan and Europe Agreements based on current development plans.
• Will not be due any royalty, development, or milestone payments under the AstraZeneca China Agreement due to the divestiture.

Risks

• Substantial dependence on the success of lead products roxadustat (for anemia in lower-risk MDS) and FG-3246 (for mCRPC).
• Drug development and obtaining marketing authorization are very difficult endeavors, and regulatory approval for product candidates may not be obtained.
• Preclinical, Phase 1, and Phase 2 clinical trial results may not be indicative of results in larger clinical trials.
• Ongoing or planned clinical trials may need to be redesigned, or sufficient patient enrollment may not be achieved, leading to delays.
• Product candidates may cause undesirable side effects or have other properties that delay or prevent regulatory approval or limit commercial potential.
• Inability to properly manufacture the appropriate volume of product may lead to delays in development, regulatory approval, launch, or successful commercialization.
• Substantial competition in the discovery, development, and commercialization of product candidates from other companies with greater resources.
• Product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community.
• Termination of collaborations or partners being unwilling or unable to contribute could adversely affect the ability to develop and commercialize product candidates.
• Reliance on third-party preclinical and clinical trial contractors, who may not perform agreed-upon obligations, leading to delays in regulatory approvals.
• Reliance on third parties for product manufacturing and distribution, with risks of termination, unsatisfactory performance, shortfalls, delays, or excesses.
• Certain components of products are acquired from single-source suppliers or without long-term supply agreements, posing supply chain risks.
• Inadequate protection of proprietary and exclusively licensed technologies may hinder competitive effectiveness.
• High cost and continuous review required for maintaining patent protection throughout major global markets.
• Laws of some foreign countries may not protect proprietary rights to the same extent as U.S. laws.
• The regulatory approval process is highly uncertain and unpredictable.
• Current and future relationships with customers, physicians, and third-party payors are subject to healthcare fraud and abuse laws, false claims laws, transparency laws, and other regulations, with potential for substantial penalties for non-compliance.
• Stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies, and other obligations related to data privacy and security, with potential for regulatory investigations, litigation, fines, and reputational harm.
• Potential costs from the wind-up of the Cayman Subsidiary and risk of not receiving some of the remaining AZ Holdbacks related to the China divestiture.
• Changes in U.S. and China relations, as well as relations with other countries, and/or regulations may adversely impact the business, including tariffs and geopolitical tensions affecting suppliers like WuXi AppTec, WuXi Biologics, and WuXi XDC.
• Exposure to currency exchange rate fluctuations and currency exchange restrictions.
• Tax inefficiencies associated with the offshore corporate structure and changes in tax provisions.
• Continued incurrence of significant losses for the foreseeable future, requiring additional financing that may be dilutive to shareholders or restrict operations.
• Potential for impairment of long-lived assets.
• The non-dilutive transaction with NovaQuest could limit cash flow, expose the company to risks, and contain covenants that could result in acceleration of payments.
• Difficulties in managing growth and expanding operations successfully.
• Exposure to risks associated with litigation, investigations, regulatory proceedings, and other legal matters.
• Product liability lawsuits could result in substantial liabilities and limit commercial operations.
• Business and operations could suffer in the event of computer system failures or cybersecurity incidents.
• The market price of common stock may be highly volatile.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Potential for dilutive acquisitions.
• Provisions in charter documents and Delaware law may have anti-takeover effects.
• No plans to pay dividends; capital appreciation is the sole possible source of gain.
• Shareholder proposals or actions could negatively affect the business or share price.

Future Outlook

FibroGen anticipates continuing to incur losses from continuing operations for the foreseeable future. However, the company believes its existing cash and cash equivalents will be sufficient to fund planned operating requirements for at least 12 months following the issuance of the financial statements for September 30, 2025. The company plans to submit the Phase 3 trial protocol for roxadustat in lower-risk MDS to the FDA in the fourth quarter of 2025, with interim results for the Phase 2 FG-3246 mCRPC study expected in the second half of 2026, and topline results from the Phase 1b/2 FG-3246 combination study in Q1 2026. FibroGen expects to reach a Payment Cap of up to $125.0 million by 2031 under the Revenue Interest Financing Agreement with NovaQuest. The company does not expect to receive most or all additional potential milestones under the Astellas Japan and Europe Agreements and will not receive royalty, development, or milestone payments under the AstraZeneca China Agreement due to the divestiture. Substantial additional funding is anticipated to be needed for continuing operations.

Management Comments

• "We initiated a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory analysis of FG-3180, in the third quarter of 2025."
• "We had a positive Type-C meeting with the U.S. Food and Drug Administration (FDA) in July 2025, and reached alignment on several elements of our proposed Phase 3 study design for roxadustat in anemia associated with lower-risk MDS, including the starting dose and the inclusion criteria."
• "We are starting preparations for the Phase 3 trial, while evaluating internal development and potential partnership opportunities for this late-stage program. We plan to submit the Phase 3 trial protocol to the FDA in the fourth quarter of 2025."
• "Based on its current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund the Companys planned operating requirements for at least the 12 months following the issuance of the financial statements for September 30, 2025."

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory processes, and intense competition. FibroGen's strategic focus on oncology (mCRPC with FG-3246) and anemia (lower-risk MDS with roxadustat) targets areas with significant unmet medical needs. The development of antibody-drug conjugates (ADCs) like FG-3246 represents a growing and innovative segment in cancer therapy, leveraging targeted delivery of cytotoxic agents. Roxadustat, as a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, offers a novel mechanism for treating anemia, potentially providing advantages over traditional erythropoiesis-stimulating agents (ESAs), especially in patients with inflammatory conditions. The divestiture of China operations allows FibroGen to streamline its focus on its core pipeline assets in key markets like the U.S., Europe, and Japan, aligning with a trend of companies optimizing their global footprints. However, the company continues to face challenges from larger pharmaceutical competitors with greater resources and must navigate complex global supply chains and geopolitical tensions, particularly concerning manufacturing partners in China.

Comparison to Industry Standards

• For metastatic castration-resistant prostate cancer (mCRPC), current standard of care treatments show radiographic progression-free survival (rPFS) of approximately 5.6-6 months after switching to a different ARPI, and approximately 8 months with chemotherapy. FG-3246's Phase 1 study showed a median rPFS of 8.7 months in all 40 subjects in the efficacy analysis set, suggesting comparable or potentially improved efficacy in this heavily pre-treated population.
• For lower-risk myelodysplastic syndromes (MDS), currently available treatment options are effective in only approximately 50% of patients. Roxadustat's Phase 2/3 MATTERHORN trial showed 47.5% of patients in the roxadustat arm achieved transfusion independence for 56 consecutive days (within 28 weeks) compared to 33.3% in the placebo arm, though the p-value was not significant. A post-hoc analysis in high transfusion burden patients (4+ pRBC units over two consecutive 8-week periods) showed 36% transfusion independence for roxadustat patients versus 7% for placebo patients (nominal p-value of 0.04), indicating potential benefit in a specific subgroup.
• NA The filing does not provide specific comparable companies, projects, or results for direct benchmarking beyond these general efficacy statements.

Legal Proceedings

• A class action lawsuit settlement of $28.5 million was fully distributed during the first quarter of 2025, with the amount fully covered by insurance.
• Entered into a settlement with the SEC in May 2025, agreeing to pay a $1.25 million civil penalty related to roxadustat's pooled cardiovascular safety data, which was approved by the Commission in September 2025.
• Seven litigation demands from purported shareholders asking the Board of Directors to investigate alleged wrongdoing were withdrawn.

Related Party Transactions

• Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca, was an unconsolidated variable interest entity (VIE) accounted for as an equity method investment and considered a related party. Product revenue from sales to Falikang was $165.3 million for Q3 2025 and $218.6 million for 9M 2025 within discontinued operations. This relationship concluded with the divestiture of China operations.
• The company has a Revenue Interest Financing Agreement (RIFA) with an affiliate of NovaQuest Capital Management (NovaQuest).

Stakeholder Impact

• Shareholders: Experienced a significant reduction in net loss and improved liquidity, but face potential future dilution from anticipated capital raises and continued operational losses from continuing operations.
• Employees: The U.S. workforce was reduced by approximately 75% in August 2024 as part of a cost reduction plan following pamrevlumab clinical results.
• Customers: Continued commercialization of roxadustat in Europe and Japan by Astellas, and ongoing development of FG-3246 and roxadustat in MDS aim to address unmet medical needs for patients.
• Creditors: The repayment of senior secured term loan facilities with MSTV reduced the company's debt burden, while obligations under the RIFA with NovaQuest continue.

Next Steps

• Submit the Phase 3 trial protocol for roxadustat in lower-risk MDS to the FDA in the fourth quarter of 2025.
• Evaluate internal development and potential partnership opportunities for roxadustat in lower-risk MDS.
• Expect interim results from the Phase 2 monotherapy dose optimization study of FG-3246 for mCRPC in the second half of 2026.
• Expect topline results from the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in the first quarter of 2026.
• Wind up FibroGen International (Cayman) Limited after the final AZ Holdback is received or finalized.
• Continue to evaluate the effects of new accounting guidance (ASU 2024-03 and ASU 2023-09) on related disclosures.

Key Dates

Recommendation

While FibroGen achieved a significant financial turnaround with a net income driven by the China divestiture and improved liquidity, its continuing operations still incur losses. The progress in FG-3246 and roxadustat in MDS is promising, but these are still in development stages with inherent risks and no guaranteed commercial success. The company anticipates needing substantial additional funding, which could lead to future dilution. The strategic refocus is positive, but the long-term profitability from the remaining pipeline is yet to be fully established. Investors should hold to monitor the progress of the clinical pipeline and the path to sustainable profitability from continuing operations.

Keywords

Biopharmaceutical, Oncology, Anemia, Prostate Cancer, mCRPC, Myelodysplastic Syndromes, MDS, FG-3246, Roxadustat, EVRENZO, ADC, CD46, HIF-PH inhibitor, Clinical Trials, FDA, SEC Filing, Divestiture, AstraZeneca, Astellas, Financial Results, Q3 2025, Liquidity, Debt Repayment, R&D, Corporate Governance, Risk Factors